Market Cap: $11.88B
BI
BioMarin Pharmaceutical Inc.
BMRN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $11.88B
BioMarin Pharmaceutical (Ticker: BMRN) showcases significant advancements in rare disease therapies, underpinned by recent presentations at the ENDO 2026 conference. The company highlights promising l…
BioMarin Pharmaceutical Inc. (Ticker: BMRN) continues to make significant strides in addressing growth disorders in children, as highlighted by new data at the recent ENDO 2026 conference in Chicago.…
BioMarin Pharmaceutical (Ticker: BMRN) announces promising results from its Phase 3 clinical trials for VOXZOGO, a treatment designed for children with hypochondroplasia, a rare form of skeletal dyspl…
BioMarin Pharmaceutical Inc. has made significant strides in addressing rare genetic disorders through its innovative research and clinical trials. The company recently provided an update on its Phase…
BioMarin Pharmaceutical (Ticker: BMRN) faces both opportunities and challenges as it navigates the complexities of developing treatments for rare genetic disorders. The recent update on its Phase 3 EN…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced significant advancements regarding its treatment for achondroplasia, VOXZOGO® (vosoritide), which has become the sole approved therapy for chi…
Creating Awareness for Rare Diseases: CNBC Cures Makes an Impact In an inspiring move to raise awareness for the 30 million Americans affected by rare diseases, CNBC has launched an initiative named "…
Insider Sale Raises Questions Amid BioMarin’s Ongoing Development BioMarin Pharmaceutical, a leader in biotechnology focused on treatments for rare diseases, finds itself in the spotlight following th…
BioMarin’s VOXZOGO® Shows Promising Results in Early Treatment for Achondroplasia BioMarin Pharmaceutical Inc. announces encouraging findings from its studies on VOXZOGO® (vosoritide), which reaffirm…
Advancements in Rare Disease Treatments: A Focus on Biomarin Pharmaceutical In the rapidly evolving landscape of biotechnology, Biomarin Pharmaceutical stands out for its commitment to addressing rare…
Biomarin Pharmaceutical: Pioneering Treatments for Rare Genetic Disorders Biomarin Pharmaceutical stands at the forefront of innovative biopharmaceutical research dedicated to addressing rare genetic…
### Scrutiny Over Gene Therapy Protocols: UniQure Faces FDA Challenges In a significant development for the gene therapy field, UniQure finds itself in a contentious standoff with the U.S. Food and Dr…
### Regulatory Challenges in Gene Therapy: A Call for Reform In recent discussions surrounding the FDA's role in the pharmaceutical industry, particularly at the CNBC Cures Summit in New York City, si…
BioMarin Expands Treatment Options for Adolescents with Phenylketonuria The U.S. Food and Drug Administration (FDA) has recently approved BioMarin Pharmaceutical Inc.'s supplemental application for Pa…
### BioMarin's Groundbreaking Approval of PALYNZIQ: A Game Changer for Pediatric PKU Treatment BioMarin Pharmaceutical Inc. recently achieves a pivotal milestone with the FDA's approval of PALYNZIQ® (…
Biomarin Pharmaceutical's Growth Trajectory Amidst Mixed Quarterly Results Biomarin Pharmaceutical Inc. finds itself at a pivotal juncture, as it reports its fourth-quarter results which reveal mixed…
BioMarin Pharmaceuticals Takes Center Stage at Key Healthcare Conferences BioMarin Pharmaceutical Inc., based in San Rafael, California, actively pursues its mission to enhance treatment options for r…
BioMarin Pharmaceutical Advances Commitment to Rare Disease Treatments at Upcoming Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reaffirms its dedication to revolutionizing care for rare dis…
Biomarin frames earnings day as a strategic program update Regulatory and Program Updates Take Center Stage Biomarin uses its Feb. 23, 2026 quarterly results as a vehicle to deliver updates on late-st…
Financing push ahead of Amicus purchase BioMarin Pharmaceutical is moving forward with a financing package to support its pending acquisition of Amicus Therapeutics, depositing gross proceeds from a n…
BioMarin Pharmaceuticals Appoints Chief Digital and Information Officer to Drive Digital Transformation BioMarin Pharmaceutical Inc. announces the appointment of Arpit Davé as its Executive Vice Presi…
BioMarin Pharmaceuticals and Veeva Systems Forge a Strategic Partnership to Accelerate Drug Development BioMarin Pharmaceutical Inc. and Veeva Systems have announced a long-term partnership aimed at e…
BioMarin and Veeva Forge Strategic Alliance to Enhance Therapeutic Development BioMarin Pharmaceutical Inc. has recently announced a significant expansion of its long-term enterprise agreement with Ve…
BioMarin Pharmaceutical Expands Portfolio with Acquisition of Amicus Therapeutics BioMarin Pharmaceutical Inc. announces a strategic acquisition of Amicus Therapeutics, Inc. in a deal valued at approx…
BioMarin Pharmaceutical Enhances Its Portfolio with Amicus Therapeutics Acquisition BioMarin Pharmaceutical Inc. announces a significant strategic move with its agreement to acquire Amicus Therapeutic…
BioMarin Pharmaceutical: Strengthening Its Position in Rare Disease Treatments Through Strategic Merger BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. have recently announced a merger that…
Biomarin Pharmaceutical: Navigating the Landscape of Rare Disease Treatment Biomarin Pharmaceutical is at the forefront of developing innovative therapies for rare genetic diseases, positioning itself…
BioMarin Advances Treatment for Phenylketonuria in Adolescents BioMarin Pharmaceutical Inc. has made a significant stride in expanding treatment options for adolescents suffering from phenylketonuria…
Biomarin's Q3 Performance Highlights Challenges in Rare Disease Therapeutics Biomarin Pharmaceutical Inc. faces significant challenges as it navigates the competitive landscape of rare disease therape…
BioMarin Advances Rare Disease Treatment Amidst Financial Setbacks BioMarin Pharmaceutical Inc. faces a complex landscape as it navigates disappointing financial results while simultaneously making st…
Biomarin's Strategic Focus on Rare Genetic Diseases Fuels Growth Prospects Biomarin Pharmaceutical is on the verge of revealing its quarterly earnings on October 27, 2025, and the company is positione…
BioMarin Pharmaceutical Faces Growing Bearish Sentiment Amid Rising Short Interest BioMarin Pharmaceutical Inc. experiences a notable increase in short interest, with a 22.93% rise since the last repo…
Increased Short Interest Signals Market Sentiment for BioMarin Pharmaceutical BioMarin Pharmaceutical, a leader in developing innovative biopharmaceuticals for rare diseases, faces rising scrutiny fro…
BioMarin Advances Treatment for Achondroplasia with VOXZOGO Findings BioMarin Pharmaceutical Inc. reveals groundbreaking insights at the American Society for Bone and Mineral Research 2025 Annual Meet…
Investor Sentiment Shifts for BioMarin Pharmaceutical Amid Modest Short Interest BioMarin Pharmaceutical Inc. (BMRN) experiences a significant shift in investor sentiment as recent reports indicate a…
BioMarin Pharmaceutical Engages with Investors Amid Expanding Pipeline BioMarin Pharmaceutical Inc., a biotechnology company renowned for its commitment to developing therapies for rare genetic disord…
BioMarin Pharmaceutical's Strategic Engagement in Healthcare Conferences BioMarin Pharmaceutical Inc., a prominent biotechnology firm based in San Rafael, California, reinforces its commitment to inno…
Biomarin Pharmaceutical: Navigating the Landscape of Rare Disease Therapies Biomarin Pharmaceutical continues to solidify its standing as a pioneer in the field of rare disease therapies. The company…
Shifting Investor Sentiment Towards BioMarin Pharmaceutical BioMarin Pharmaceutical experiences a notable shift in investor sentiment as its short interest decreases by 15.79% since the last report. C…
Biomarin Pharmaceutical’s Robust Growth in Q2 Highlights Strategic Success Biomarin Pharmaceutical Inc. showcases a significant upward trajectory in its second-quarter results, affirming its strong po…
Biomarin Pharmaceutical Prepares for Key Earnings Announcement Biomarin Pharmaceutical, a leader in innovative therapies for rare diseases, is poised to release its quarterly earnings report on August…
FDA Approves New Treatment for Phenylketonuria: A Step Forward in Rare Disease Management In a significant advancement for rare disease treatment, the U.S. Food and Drug Administration (FDA) recently…
Biomarin's Competitive Landscape in PKU Treatments The recent FDA approval of PTC Therapeutics' drug PTCT SEPHIENCE (sepiapterin) for the treatment of phenylketonuria (PKU) introduces a new player int…
BioMarin Pharmaceutical Faces Increased Short Interest Amid Market Dynamics BioMarin Pharmaceutical experiences a notable rise in short interest, with a 47.64% increase in the percentage of its float…
Rising Short Interest Signals Increased Bearish Sentiment for BioMarin Pharmaceutical BioMarin Pharmaceutical experiences a notable surge in short interest, as the percentage of its float sold short e…
Biomarin Pharmaceutical's Position in the Biotech Landscape Biomarin Pharmaceutical stands at the forefront of the biotechnology sector, particularly as it navigates a landscape defined by innovation…
BioMarin Pharmaceutical: A Bright Spot in Biotech Amid Economic Uncertainty As the biotechnology sector navigates through a tumultuous economic landscape characterized by rising inflation and concerns…
BioMarin Pharmaceutical: Positioned for Growth Amidst Market Optimism BioMarin Pharmaceutical is gaining attention as analysts express optimism for the company as they look toward the second half of 2…
Biomarin Pharmaceutical: Advancements in Rare Disease Treatments Biomarin Pharmaceutical focuses on developing innovative therapies for patients with serious, life-threatening rare diseases. The compa…
BioMarin Pharmaceutical: Rethinking the Orphan Drug Paradigm BioMarin Pharmaceutical publicly voices its discontent with the current orphan drug model, signaling a critical juncture for the company an…